The startup has three SBIR grants, totaling $1,960,850 from the National Institutes of Health, Department of Health and Human Services for both drug target identification and also developing a treatment for insulin resistance.
Paul Riat is just this guy, trying to figure things out. A fan of Max Weber, he generally gets a kick out of the triangle between economy, society and liberty. His focus on technology startups and venture capital fits because early stage tech startups are the most dynamic and impactful elements of local economies -- improving liberty and society like a rising tide.
